Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department

被引:10
作者
Hasara, Shannon [1 ,4 ]
Dubey, Jesse [2 ]
Amatea, John [2 ]
Finnigan, Nancy [3 ]
机构
[1] Lakeland Reg Hlth, Dept Pharm, 1324 Lakeland Hills Blvd, Lakeland, FL 33805 USA
[2] Lakeland Reg Hlth, Dept Emergency Med, 1324 Lakeland Hills Blvd, Lakeland, FL 33805 USA
[3] Lakeland Reg Hlth, Dept Nephrol, 1324 Lakeland Hills Blvd, Lakeland, FL 33805 USA
[4] Dept Pharm, 1324 Lakeland Hills Blvd, Lakeland, FL 33805 USA
关键词
Hyperkalemia; Potassium; Sodium polystyrene sulfonate; Sodium zirconium cyclosilicate; Emergency department; SERUM POTASSIUM; MANAGEMENT; ZS-9;
D O I
10.1016/j.ajem.2022.12.043
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Hyperkalemia accounts for over 800,000 emergency department (ED) visits in the United States each year, and has been associated with significant morbidity and mortality likely due to fatal cardiac dysrhyth-mias. Previous studies have demonstrated reductions in mortality when potassium levels are normalized in the ED. Cation exchange resins, such as sodium polystyrene sulfonate (SPS) and sodium zirconium cyclosilicate (SZC), may be administered as a means of definitively eliminating potassium from the body. This practice is based on physician preference and is not supported by high quality data. Two studies evaluating the use of cation exchange resins versus standard treatment in the ED demonstrated reductions in serum potassium levels within two hours of administration; however, there have been no published studies investigating these agents in a head-to-head comparison. Objective: The purpose of this study was to evaluate the efficacy and safety of SPS versus SZC in lowering serum potassium in patients presenting to the ED with hyperkalemia. Methods: This was an institutional review board-approved, retrospective cohort study conducted at a single-site ED. All patients who received medications under the "ED Hyperkalemia Treatment" order set between August 26, 2019 and May 13, 2021 were eligible for inclusion. The primary outcome was the change in serum potassium from baseline to first repeat level following SPS or SZC administration in the ED.Results: A total of 885 patients were screened with 54 patients in the SPS group and 51 patients in the SZC group included in the final analyses. The mean change in serum potassium from baseline to first repeat level following administration of the cation exchange resin was -1.1 mEq/L for both groups.Conclusion: Administration of SPS or SZC for the treatment of hyperkalemia in the ED resulted in similar reduc-tions in serum potassium. (c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:59 / 64
页数:6
相关论文
共 31 条
[1]   TRENDS IN EMERGENCY ROOM VISITS DUE TO HYPERKALEMIA IN THE UNITED STATES [J].
Aggarwal, S. ;
Topaloglu, H. ;
Kumar, S. .
VALUE IN HEALTH, 2015, 18 (07) :A386-A386
[2]   Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial [J].
Anker, Stefan D. ;
Kosiborod, Mikhail ;
Zannad, Faiez ;
Pina, Ileana L. ;
McCullough, Peter A. ;
Filippatos, Gerasimos ;
van der Meer, Peter ;
Ponikowski, Piotr ;
Rasmussen, Henrik S. ;
Lavin, Philip T. ;
Singh, Bhupinder ;
Yang, Alex ;
Deedwania, Prakash .
EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (10) :1050-1056
[3]  
Batterink Josh, 2015, Can J Hosp Pharm, V68, P296, DOI 10.4212/cjhp.v68i4.1469
[4]   Secondary Prevention of Hyperkalemia With Sodium Polystyrene Sulfonate in Cardiac and Kidney Patients on Renin-Angiotensin-Aldosterone System Inhibition Therapy [J].
Chernin, Gil ;
Gal-Oz, Amir ;
Ben-Assa, Eyal ;
Schwartz, Idit F. ;
Weinstein, Talia ;
Schwartz, Doron ;
Silverberg, Donald S. .
CLINICAL CARDIOLOGY, 2012, 35 (01) :32-36
[5]  
De Vecchis R, 2021, EUR J CASE REP INTER, V8
[6]   Management of hyperkalemia in the acutely ill patient [J].
Depret, Francois ;
Peacock, W. Frank ;
Liu, Kathleen D. ;
Rafique, Zubaid ;
Rossignol, Patrick ;
Legrand, Matthieu .
ANNALS OF INTENSIVE CARE, 2019, 9 (1)
[7]  
Gruy-Kapral C, 1998, J AM SOC NEPHROL, V9, P1924
[8]   Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study [J].
Hagan, Amanda E. ;
Farrington, Crystal A. ;
Wall, Geoffrey C. ;
Belz, Mark M. .
CLINICAL NEPHROLOGY, 2016, 85 (01) :38-43
[9]   THE SEQUENCING OF MEDICATION ADMINISTRATION IN THE MANAGEMENT OF HYPERKALEMIA [J].
Hall, Aaron B. ;
Salazar, Manuel ;
Larison, Deborah J. .
JOURNAL OF EMERGENCY NURSING, 2009, 35 (04) :339-342
[10]   Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia The HARMONIZE Randomized Clinical Trial [J].
Kosiborod, Mikhail ;
Rasmussen, Henrik S. ;
Lavin, Philip ;
Qunibi, Wajeh Y. ;
Spinowitz, Bruce ;
Packham, David ;
Roger, Simon D. ;
Yang, Alex ;
Lerma, Edgar ;
Singh, Bhupinder .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (21) :2223-2233